AMZEEQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Amzeeq, and when can generic versions of Amzeeq launch?
Amzeeq is a drug marketed by Journey and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-five patent family members in ten countries.
The generic ingredient in AMZEEQ is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amzeeq
A generic version of AMZEEQ was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMZEEQ?
- What are the global sales for AMZEEQ?
- What is Average Wholesale Price for AMZEEQ?
Summary for AMZEEQ
| International Patents: | 25 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Clinical Trials: | 1 |
| Patent Applications: | 2,826 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AMZEEQ |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AMZEEQ |
| What excipients (inactive ingredients) are in AMZEEQ? | AMZEEQ excipients list |
| DailyMed Link: | AMZEEQ at DailyMed |
Recent Clinical Trials for AMZEEQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Edward Lain, MD | Phase 4 |
| Vyne Therapeutics Inc. | Phase 4 |
Pharmacology for AMZEEQ
| Drug Class | Tetracycline-class Drug |
| Physiological Effect | Decreased Prothrombin Activity |
Paragraph IV (Patent) Challenges for AMZEEQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AMZEEQ | Topical Aerosol Foam | minocycline hydrochloride | 4% | 212379 | 1 | 2021-05-11 |
US Patents and Regulatory Information for AMZEEQ
AMZEEQ is protected by twelve US patents.
Patents protecting AMZEEQ
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Compositions, gels and foams with rheology modulators and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treating rosacea and acne
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Method for healing of an infected acne lesion without scarring
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Compositions and methods for treating rosacea and acne
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-NODULAR ACNE VULGARIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | AMZEEQ | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 212379-001 | Oct 18, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Journey | AMZEEQ | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 212379-001 | Oct 18, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | AMZEEQ | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 212379-001 | Oct 18, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMZEEQ
See the table below for patents covering AMZEEQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011138678 | ⤷ Sign Up | |
| Brazil | 112012007473 | composições tópicas de tetraciclina e respectivo método de uso | ⤷ Sign Up |
| Mexico | 2020012139 | COMPOSICIONES Y METODOS PARA TRATAR ROSACEA Y ACNE. (COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE.) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
